- Home
- DRCT vs ICU Comparison
DRCT vs ICU Comparison
Compare DRCT & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- ICU
- Stock Information
- Founded
- DRCT 2018
- ICU 2018
- Country
- DRCT United States
- ICU United States
- Employees
- DRCT N/A
- ICU N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- ICU Health Care
- Exchange
- DRCT Nasdaq
- ICU Nasdaq
- Market Cap
- DRCT 11.4M
- ICU 9.5M
- IPO Year
- DRCT 2022
- ICU N/A
- Fundamental
- Price
- DRCT $0.60
- ICU $0.75
- Analyst Decision
- DRCT Strong Buy
- ICU
- Analyst Count
- DRCT 1
- ICU 0
- Target Price
- DRCT $6.00
- ICU N/A
- AVG Volume (30 Days)
- DRCT 580.2K
- ICU 4.6M
- Earning Date
- DRCT 08-05-2025
- ICU 08-12-2025
- Dividend Yield
- DRCT N/A
- ICU N/A
- EPS Growth
- DRCT N/A
- ICU N/A
- EPS
- DRCT N/A
- ICU N/A
- Revenue
- DRCT $48,170,000.00
- ICU $428,000.00
- Revenue This Year
- DRCT $50.71
- ICU $754.07
- Revenue Next Year
- DRCT $26.31
- ICU $100.09
- P/E Ratio
- DRCT N/A
- ICU N/A
- Revenue Growth
- DRCT N/A
- ICU N/A
- 52 Week Low
- DRCT $0.44
- ICU $0.31
- 52 Week High
- DRCT $6.59
- ICU $8.38
- Technical
- Relative Strength Index (RSI)
- DRCT 58.19
- ICU 51.94
- Support Level
- DRCT $0.50
- ICU $0.53
- Resistance Level
- DRCT $0.79
- ICU $0.94
- Average True Range (ATR)
- DRCT 0.06
- ICU 0.10
- MACD
- DRCT 0.00
- ICU 0.01
- Stochastic Oscillator
- DRCT 33.57
- ICU 53.93
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.